Abbott (ABT)

• Market cap: $227B
• 1 day: -0.40%
• 5 days: 2.84%
• 1 month: -5.21%
• 3 months: 15.98%
• 6 months: 14.74%
• Year to date: 15.32%
• 1 year: 15.10%
• 5 years: 64.89%
• 10 years: 177.87%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Employees: 114,000

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

182% more first-time investments, than exits

New positions opened: 293 | Existing positions closed: 104

25% more call options, than puts

Call options by funds: $1.25B | Put options by funds: $999M

14% more funds holding in top 10

Funds holding in top 10: 63 [Q3] → 72 (+9) [Q4]

4% more funds holding

Funds holding: 2,853 [Q3] → 2,977 (+124) [Q4]

1.87% more ownership

Funds ownership: 75.95% [Q3] → 77.82% (+1.87%) [Q4]

3% more capital invested

Capital invested by funds: $151B [Q3] → $155B (+$4.61B) [Q4]

4% less repeat investments, than reductions

Existing positions increased: 1,106 | Existing positions reduced: 1,149

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $135 3% upside
• Avg. target: $147 12% upside
• High target: $160 22% upside

8 analyst ratings

• positive: 8 100%
• neutral: 0 0%
• negative: 0 0%

B of A Securities Travis Steed 33% 1-year accuracy 2 / 6 met price target	15% upside $150	Buy Maintained	10 Mar 2025
Citigroup Joanne Wuensch 43% 1-year accuracy 22 / 51 met price target	22% upside $160	Buy Maintained	4 Mar 2025
Goldman Sachs David Roman 30% 1-year accuracy 6 / 20 met price target	18% upside $154	Buy Maintained	4 Mar 2025
Barclays Matt Miksic 59% 1-year accuracy 24 / 41 met price target	21% upside $158	Overweight Maintained	27 Jan 2025
RBC Capital Shagun Singh 60% 1-year accuracy 40 / 67 met price target	3% upside $135	Outperform Reiterated	23 Jan 2025